For severe asthma and airway hyperreactivity, biologics offer targeted treatment—addressing specific inflammatory pathways. These therapies are reshaping the bronchial hyperreactivity market.

Within the Bronchial Hyperreactivity Market, biologics are the fastest-growing segment.

Geographically, adoption is strongest in advanced markets.

Looking ahead, biologics will grow. For stakeholders, innovation is key.

People Also Ask

What biologics treat severe asthma?
Anti-IgE, anti-IL-5, and anti-IL-4 therapies—among others.

Are biologics effective for airway hyperreactivity?
They can reduce exacerbations—efficacy depends on phenotype.

Tags

#Biologics #SevereAsthma #BronchialHyperreactivity #RespiratoryMedicine #Innovation #Pulmonology